Dr. Henrich Guntermann, MD, MSc,
President, Europe & Immunology Group

The Immunology Group is located in Germany and includes a research and development facility in Leipzig and a manufacturing facility in Wanzleben.  The focus of the Group is the development of WF10 for the treatment of immune related diseases.  WF10 is a solution of OXO-K993 containing stabilized chlorite ions.

The immune system provides an essential defence to micro-organisms, cancer and substances it sees as foreign and potentially harmful.  WF10 focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function.

In 2010, the Company completed a Phase 2 allergic rhinitis clinical trial utilizing WF10, that met its primary endpoint. The Immunology Group is currently completing its analysis of the study data and reviewing this data with key opinion leaders specializing in immunology, airway diseases and rheumatoid arthritis to determine the necessary development and regulatory program including timing and costs and examining the commercial opportunities for WF10.